Advanced Oncotherapy (AVO) – Financing facility provided by significant shareholders

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a consortium formed by AB Segulah and other investors has made available a £3.9m loan to the Company.  The loan will have a two year maturity and a 12% per annum rolled up interest rate.  The Segulah group includes AB Segulah, a […]